NDA 217026 · Acadia Pharms INC
Daybue
Trofinetide · Oral
NovelPriority reviewOrphanCDER novel approval, Mar 10, 2023: To treat Rett syndrome
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Mar 10, 2023
Approved uses
3
Original approval plus efficacy supplements
Registered trials
12
4 Phase 3, 0 recruiting
FAERS reports
6,891
2,007 serious, 42 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 4, 2026.
DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. DAYBUE and DAYBUE STIX are indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. ( 1 )
Mechanism: The mechanism by which trofinetide exerts therapeutic effects in patients with Rett syndrome is unknown.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2026 Supplement 8 · Efficacy · priority review OrphanLabelLetter
- Sep 30, 2024 Supplement 1 · Efficacy OrphanLabelLetter
- Mar 10, 2023 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- DAYBUE · TROFINETIDE 200MG/ML · SOLUTION, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trofinetide" as an intervention, any sponsor and status, largest first.
- Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFICPivotal-lookingCompleted
Neuren Pharmaceuticals LimitedIndustry
NCT01366820 · 261 participants · Start Feb 2013 · Primary completion Jan 2016
Drug: NNZ-2566; Placebo · For: Brain Injuries
Sites: Colton, California; Sacramento, California; Honolulu, Hawaii · 6 sites in all
- Study of NNZ-2566 in Patients With Traumatic Brain InjuryPivotal-lookingCompleted
Neuren Pharmaceuticals LimitedIndustry
NCT00805818 · 261 participants · Start Apr 2010 · Primary completion Jan 2016
Drug: NNZ-2566; Placebo · For: Brain Injuries
Sites: Mobile, Alabama; Tucson, Arizona; Colton, California · 20 sites in all
- Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)Pivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT04181723 · 187 participants · Start Nov 6, 2019 · Primary completion Oct 28, 2021
Drug: Trofinetide · For: Rett Syndrome
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 21 sites in all
- Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromePivotal-lookingCompleted
ACADIA Pharmaceuticals Inc.Industry
NCT04279314 · 154 participants · Start Jan 29, 2020 · Primary completion Aug 19, 2022
Drug: Trofinetide · For: Rett Syndrome
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 21 sites in all
Neuren Pharmaceuticals LimitedIndustry
NCT02715115 · 82 participants · Start Mar 2016 · Primary completion Jan 5, 2017
Drug: NNZ-2566; Placebo · For: Rett Syndrome
Sites: Birmingham, Alabama; Oakland, California; San Diego, California · 12 sites in all
- Open-Label Extension Study of Trofinetide for Rett SyndromePivotal-lookingTerminated
ACADIA Pharmaceuticals Inc.Industry
NCT04776746 · 77 participants · Start Nov 8, 2020 · Primary completion Jun 30, 2023
Drug: trofinetide · For: Rett Syndrome
Sites: Birmingham, Alabama; Phoenix, Arizona; La Jolla, California · 21 sites in all
Neuren Pharmaceuticals LimitedIndustry
NCT01894958 · 72 participants · Start Jan 2014 · Primary completion Sep 2015
Drug: NNZ-2566; Placebo · For: Fragile X Syndrome
Sites: Sacramento, California; Denver, Colorado; Washington D.C., District of Columbia · 17 sites in all
Neuren Pharmaceuticals LimitedIndustry
NCT01703533 · 67 participants · Start Mar 2013 · Primary completion Sep 2014
Drug: NNZ-2566; Placebo · For: Rett Syndrome
Sites: Birmingham, Alabama; Saint Paul, Minnesota; Houston, Texas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- diarrhoea3,750
- underdose2,082
- vomiting1,187
- product dose omission issue909
- seizure882
- constipation700
- product use complaint655
- weight decreased609
- intentional dose omission484
- drug ineffective481
- decreased appetite424
- nasopharyngitis389
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2020 | 1 |
| 2023 | 1,120 |
| 2024 | 1,820 |
| 2025 | 2,524 |
| 2026 | 1,426 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Daybue (Trofinetide)
2024 spending
$39.6M
Beneficiaries
93
667 claims
Per beneficiary
$425,972
$22.96 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $19,168,240 |
| 2024 | $39,615,371 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study.
Neul JL, Percy AK, Benke TA, et al. · Nat Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Trofinetide for the treatment of Rett syndrome: Results from the open-label extension LILAC study.
Percy AK, Neul JL, Benke TA, et al. · Med 2024 · Multicenter Study, Randomized Controlled Trial
- Exposure-Response Efficacy Modeling to Support Trofinetide Dosing in Individuals with Rett Syndrome.
Darwish M, Passarell J, Youakim JM, et al. · Adv Ther 2024 · Clinical Trial, Phase III, Research Support, Non-U.S. Gov't
- A meta-analysis of the efficacy and safety of trofinetide in patients with rett syndrome.
Abo Zeid M, Elrosasy A, Mohamed RG, et al. · Neurol Sci 2024 · Meta-Analysis
- Is trofinetide a future treatment for Rett syndrome? A comprehensive systematic review and meta-analysis of randomized controlled trials.
Mohammed HE, Bady Z, Haseeb ME, et al. · BMC Med 2024 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome.
Neul JL, Percy AK, Benke TA, et al. · Pediatr Neurol 2024 · Randomized Controlled Trial
Sponsor: Acadia Pharms INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.